Autoimmune Diseases  >>  Ozespa (briakinumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ozespa (briakinumab) / AbbVie
NCT00086671: Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)

Completed
2
215
US, Canada, Europe
ABT-874/Human monoclonal antibody against IL-12, Placebo
AbbVie (prior sponsor, Abbott)
Multiple Sclerosis
11/06
11/06

Download Options